MDT-AP-1106
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 23.04
- os_event
- false
- age_years
- 4.9
- sex
- M
- new_clusters
- S2
- umap1_2d
- -1.357310519
- umap2_2d
- -9.216840064
- umap1_3d
- -3.300980544
- umap2_3d
- -1.56894386
- umap3_3d
- 5.484758387
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- E2F_TARGETS+0.470
- IL6_JAK_STAT3_SIGNALING+0.460
- MYC_TARGETS_V1+0.440
- ALLOGRAFT_REJECTION+0.420
- COAGULATION+0.410
- INFLAMMATORY_RESPONSE+0.410
- ANGIOGENESIS+0.390
- G2M_CHECKPOINT+0.390
- INTERFERON_ALPHA_RESPONSE+0.380
Top 10 suppressed
- PROTEIN_SECRETION-0.180
- HEDGEHOG_SIGNALING-0.150
- WNT_BETA_CATENIN_SIGNALING-0.140
- PI3K_AKT_MTOR_SIGNALING-0.080
- HEME_METABOLISM-0.070
- SPERMATOGENESIS-0.020
- TGF_BETA_SIGNALING+0.000
- PANCREAS_BETA_CELLS+0.010
- KRAS_SIGNALING_DN+0.040
- ADIPOGENESIS+0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-2822 | Med | Medulloblastoma | 0.918 |
| 2 | MDT-AP-2131 | Med | Medulloblastoma | 0.915 |
| 3 | MDT-AP-0348 | Med | Medulloblastoma | 0.914 |
| 4 | AE47BCDE-A2D2-43EF-8EC7-78E4D1817EEE | — | — | 0.911 |
| 5 | MDT-AP-0428 | Med | Medulloblastoma | 0.907 |
| 6 | BS_M85CXHDV | high-grade glioma | — | 0.903 |
| 7 | SRR8942992 | — | — | 0.903 |
| 8 | MDT-AP-3087 | Med | Medulloblastoma | 0.902 |
| 9 | 5063882F-6377-4976-BB48-7275D46C44E6 | — | — | 0.898 |
| 10 | AUR-AFUI-TTP1-A-1-0-R-A743-41 | — | C | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.470 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.440 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.390 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.380 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.350 | Idelalisib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.340 | Inavolisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.290 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.280 | Inavolisib | — uncovered |